Fate Therapeutics, Inc. (FATE) financial statements (2021 and earlier)

Company profile

Business Address 3535 GENERAL ATOMICS COURT
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments16710019189926549
Cash and cash equivalents16710019189896549
Short-term investments    4  
Receivables6 1    
Other undisclosed current assets3211271414111
Total current assets:494227205103936650
Noncurrent Assets
Operating lease, right-of-use asset6723
Property, plant and equipment321153221
Long-term investments and receivables 39     
Long-term investments 39     
Contract with customer, asset, net1412
Restricted cash and investments15000000
Other noncurrent assets0010000
Total noncurrent assets:1287583221
TOTAL ASSETS:622302213105956851
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2221159534
Accounts payable6642111
Accrued liabilities1615117422
Employee-related liabilities      1
Deferred revenue213
Debt 22 882
Deferred revenue and credits2220
Contract with customer, liability8
Other undisclosed current liabilities4332  0(1)
Total current liabilities:8628271115135
Noncurrent Liabilities
Long-term debt and lease obligation9425121531118
Long-term debt, excluding current maturities  121531118
Operating lease, liability9425
Liabilities, other than long-term debt464112460
Deferred revenue and credits2350
Accounts payable and accrued liabilities  10110
Deferred revenue464
Contract with customer, liability8
Deferred rent credit  3
Total noncurrent liabilities:14029241771618
Total liabilities:226575128223023
Stockholders' equity
Stockholders' equity attributable to parent38424516077733828
Preferred stock00000  
Common stock0000000
Additional paid in capital941628446296249180141
Accumulated other comprehensive income (loss)00(0)(0)(0)  
Accumulated deficit(557)(384)(285)(219)(176)(142)(112)
Total stockholders' equity:38424516077733828
Other undisclosed liabilities and equity1211    
TOTAL LIABILITIES AND EQUITY:622302213105956851

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net442 
Gross profit:31115442 
Operating expenses(160)(111)(72)(46)(36)(30)(25)
Operating loss:(128)(101)(67)(42)(32)(28)(25)
Nonoperating income (expense)(43)31(1)(1)(2)(1)
Investment income, nonoperating2 0   0
Other nonoperating income (expense)(45)30(1)(1)(2)(1)
Interest and debt expense (2)(2)(0)(2)(2)(1)
Loss before gain (loss) on sale of properties:(171)(100)(68)(43)(35)(32)(27)
Other undisclosed net income (loss)(2)21    
Net loss:(173)(98)(67)(43)(35)(32)(27)
Other undisclosed net income attributable to parent   0221
Net loss available to common stockholders, diluted:(173)(98)(67)(43)(33)(30)(26)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(173)(98)(67)(43)(35)(32)(27)
Other undisclosed comprehensive income00002  
Comprehensive loss, net of tax, attributable to parent:(173)(98)(67)(43)(33)(32)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: